- Home
- NRIX
as 11-21-2024 4:00pm EST
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.3B | IPO Year: | 2020 |
| Target Price: | $29.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.65 - $29.56 | Next Earning Date: | 10-11-2024 |
| Revenue: | $56,424,000 | Revenue Growth: | -17.76% |
| Revenue Growth (this year): | -27.41% | Revenue Growth (next year): | 7.17% |
Stock Insider Trading Activity of Nurix Therapeutics Inc. Common stock (NRIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ring Christine | NRIX | Chief Legal Officer | Nov 4 '24 | Sell | $25.00 | 3,290 | $82,250.00 | 28,084 | |
| Ring Christine | NRIX | Chief Legal Officer | Nov 1 '24 | Sell | $24.28 | 5,760 | $139,866.62 | 28,084 | |
| Ring Christine | NRIX | Chief Legal Officer | Oct 1 '24 | Sell | $22.50 | 5,760 | $128,017.33 | 28,084 | |
| Ring Christine | NRIX | Chief Legal Officer | Sep 3 '24 | Sell | $25.27 | 9,050 | $225,735.92 | 28,084 | |
| van Houte Hans | NRIX | Chief Financial Officer | Aug 26 '24 | Sell | $25.22 | 20,000 | $504,370.00 | 31,002 | |
| Ring Christine | NRIX | Chief Legal Officer | Aug 26 '24 | Sell | $25.01 | 9,870 | $246,842.78 | 28,084 |
Latest Nurix Therapeutics Inc. Common stock News
NRIX Breaking Stock News: Dive into NRIX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe
GlobeNewswire
2 days ago
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
GlobeNewswire
5 days ago
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
GlobeNewswire
17 days ago
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire
22 days ago
Nurix Therapeutics to Participate in Upcoming Investor Conferences
MT Newswires
a month ago
UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target
GlobeNewswire
a month ago
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
Clinical Trials Arena
a month ago
Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial
Compare NRIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRIX Nurix Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.